- Report
- February 2026
Global
From €4382EUR$4,900USD£3,747GBP
- Report
- September 2025
- 100 Pages
Global
From €4382EUR$4,900USD£3,747GBP
- Report
- February 2026
- 187 Pages
Global
From €3231EUR$3,613USD£2,762GBP
€3801EUR$4,250USD£3,250GBP
- Report
- August 2026
- 389 Pages
Global
From €5232EUR$5,850USD£4,473GBP
- Report
- August 2026
- 175 Pages
Global
From €5232EUR$5,850USD£4,473GBP
- Report
- August 2026
- 376 Pages
Global
From €5232EUR$5,850USD£4,473GBP
- Report
- January 2026
- 180 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- January 2026
- 185 Pages
Global
From €4024EUR$4,500USD£3,441GBP
- Report
- February 2026
- 250 Pages
Global
From €4015EUR$4,490USD£3,433GBP
- Report
- February 2026
- 250 Pages
Global
From €4015EUR$4,490USD£3,433GBP
- Report
- April 2026
- 30 Pages
Global
From €2459EUR$2,750USD£2,103GBP
- Report
- November 2025
- 200 Pages
Global
From €7110EUR$7,950USD£6,079GBP
- Report
- August 2026
- 202 Pages
Global
From €5232EUR$5,850USD£4,473GBP
- Report
- May 2026
- 30 Pages
Global
From €2459EUR$2,750USD£2,103GBP
- Report
- July 2026
- 140 Pages
Global
From €4248EUR$4,750USD£3,632GBP
- Report
- May 2026
- 150 Pages
Global
From €2494EUR$2,789USD£2,132GBP
- Report
- April 2026
- 135 Pages
Global
From €2682EUR$2,999USD£2,293GBP
€3576EUR$3,999USD£3,058GBP
- Report
- September 2025
- 150 Pages
Global
From €3980EUR$4,450USD£3,402GBP
- Report
- April 2026
- 118 Pages
Global
From €3500EUR$4,192USD£3,097GBP
- Report
- October 2025
- 84 Pages
Global
From €3500EUR$4,192USD£3,097GBP

Nintedanib is a drug used to treat respiratory diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is a tyrosine kinase inhibitor that works by blocking the activity of certain proteins that are involved in the development of fibrosis. Nintedanib is approved by the US Food and Drug Administration (FDA) for the treatment of IPF and SSc-ILD. It is also approved in Europe and other countries for the treatment of IPF.
Nintedanib is marketed by Boehringer Ingelheim, a German pharmaceutical company. Other companies involved in the market include Novartis, AstraZeneca, and GlaxoSmithKline. Show Less Read more